Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, topping analysts' consensus estimates of ($1.02) by $0.24, Zacks reports.
Corbus Pharmaceuticals Price Performance
Shares of NASDAQ CRBP traded down $0.03 during midday trading on Tuesday, hitting $6.77. The stock had a trading volume of 32,961 shares, compared to its average volume of 241,246. The firm has a market cap of $82.39 million, a P/E ratio of -1.43 and a beta of 2.63. Corbus Pharmaceuticals has a fifty-two week low of $6.54 and a fifty-two week high of $61.90. The company's 50-day simple moving average is $9.87 and its 200 day simple moving average is $19.90.
Analyst Ratings Changes
Several analysts have recently weighed in on the stock. William Blair began coverage on shares of Corbus Pharmaceuticals in a research report on Friday, February 28th. They set an "outperform" rating on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $75.00 price target on shares of Corbus Pharmaceuticals in a research note on Tuesday, February 18th. StockNews.com upgraded shares of Corbus Pharmaceuticals to a "sell" rating in a research report on Thursday, March 6th. Finally, Piper Sandler initiated coverage on Corbus Pharmaceuticals in a research report on Monday, December 2nd. They set an "overweight" rating and a $35.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $63.57.
Get Our Latest Stock Analysis on Corbus Pharmaceuticals
About Corbus Pharmaceuticals
(
Get Free Report)
Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Corbus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corbus Pharmaceuticals wasn't on the list.
While Corbus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
